China Universal Asset Management Co. Ltd. Takes Position in Indivior PLC (NASDAQ:INDV)

China Universal Asset Management Co. Ltd. acquired a new position in Indivior PLC (NASDAQ:INDV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 28,906 shares of the company’s stock, valued at approximately $359,000.

Several other large investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Indivior by 4.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after acquiring an additional 1,888 shares during the period. Cubist Systematic Strategies LLC raised its holdings in Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after purchasing an additional 6,121 shares during the last quarter. Geode Capital Management LLC lifted its position in Indivior by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 132,239 shares of the company’s stock valued at $1,289,000 after purchasing an additional 9,500 shares during the period. Stifel Financial Corp bought a new position in shares of Indivior in the 3rd quarter valued at about $100,000. Finally, Melqart Asset Management UK Ltd acquired a new stake in shares of Indivior during the 3rd quarter worth approximately $132,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Down 2.5 %

Shares of INDV stock opened at $11.90 on Monday. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -297.43 and a beta of 0.74. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $23.22. The firm has a fifty day moving average of $11.80 and a 200-day moving average of $11.05.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Craig Hallum reduced their price objective on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, October 11th. Rodman & Renshaw initiated coverage on Indivior in a research note on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective for the company. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Piper Sandler restated an “overweight” rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.